NG2-mediated Rho activation promotes amoeboid invasiveness of cancer cells

European Journal of Cell Biology

Volumn 91, Issue 11-12, 2012, Pages 969-977

  Paňková, Daniela ^a   Jobe, Njainday ^a   Kratochvílová, Magdalena ^a   Buccione, Roberto ^b   Brábek, Jan ^a   Rösel, Daniel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Tumour Cell Invasion Laboratory   (Italy)

Author keywords

Amoeboid; Invadopodia; Invasiveness; Mesenchymal; NG2; Rho

Indexed keywords

CHONDROITIN SULFATE PROTEOGLYCAN NG2; COLLAGEN; PROTEOGLYCAN; RHO FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INVASION; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MESENCHYME CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHONDROITIN SULFATE PROTEOGLYCANS; COLLAGEN; DOWN-REGULATION; EXTRACELLULAR MATRIX; HUMANS; MEMBRANE PROTEINS; MOLECULAR CONFORMATION; NEOPLASM INVASIVENESS; NEOPLASMS; RATS; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84867405335     PISSN: 01719335     EISSN: 16181298     Source Type: Journal    
DOI: 10.1016/j.ejcb.2012.05.001     Document Type: Article

References (32)

1. Ayala I., Baldassarre M., Giacchetti G., Caldieri G., Tetè S., Luini A., Buccione R. Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J. Cell Sci. 2008, 121:369-378.
2. Baldassarre M., Pompeo A., Beznoussenko G., Castaldi C., Cortellino S., McNiven M.A., Luini A., Buccione R. Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol. Biol. Cell 2003, 14:1074-1084.
3. Barritt D.S., Pearn M.T., Zisch A.H., Lee S.S., Javier R.T., Pasquale E.B., Stallcup W.B. The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J. Cell. Biochem. 2000, 79:213-224.
4. Behm F.G., Smith F.O., Raimondi S.C., Pui C.H., Bernstein I.D. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996, 87:1134-1139.
5. Benassi M.S., Pazzaglia L., Chiechi A., Alberghini M., Conti A., Cattaruzza S., Wassermann B., Picci P., Perris R. NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J. Orthop. Res. 2009, 27:135-140.
6. Buccione R., Baldassarre M., Trapani V., Catalano C., Pompeo A., Brancaccio A., Giavazzi R., Luini A., Corda D. Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. Eur. J. Cancer 2005, 41:470-476.
7. Burg M.A., Tillet E., Timpl R., Stallcup W.B. Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem. 1996, 271:26110-26116.
8. Burg M.A., Grako K.A., Stallcup W.B. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol. 1998, 177:299-312.
9. Caldieri G., Ayala I., Attanasio F., Buccione R. Cell and molecular biology of invadopodia. Int. Rev. Cell Mol. Biol. 2009, 275:1-34.
10. Cavanna T., Pokorná E., Veselý P., Gray C., Zicha D. Evidence for protein 4.1B acting as a metastasis suppressor. J. Cell Sci. 2007, 120:606-616.
11. Chekenya M., Rooprai H.K., Davies D., Levine J.M., Butt A.M., Pilkington G.J. The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int. J. Dev. Neurosci. 1999, 17:421-435.
12. Ernkvist M., Luna Persson N., Audebert S., Lecine P., Sinha I., Liu M., Schlueter M., Horowitz A., Aase K., Weide T., Borg J.P., Majumdar A., Holmgren L. The Amot/Patj/Syx signaling complex spatially controls RhoA GTPase activity in migrating endothelial cells. Blood 2009, 113:244-253.
13. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr. Opin. Cell Biol. 2004, 16:14-23.
14. Janostiak R., Tolde O., Bruhová Z., Novotny M., Hanks S.K., Rosel D., Brábek J. Tyrosine phosphorylation within the SH3 domain regulates CAS subcellular localization, cell migration, and invasiveness. Mol. Biol. Cell 2011, 22:4256-4267.
15. Lämmermann T., Sixt M. Mechanical modes of 'amoeboid' cell migration. Curr. Opin. Cell Biol. 2009, 21:636-644.
16. Monnier P.P., Sierra A., Schwab J.M., Henke-Fahle S., Mueller B.K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 2003, 22:319-330.
17. Nishiyama A., Dahlin K.J., Prince J.T., Johnstone S.R., Stallcup W.B. The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol. 1991, 114:359-371.
18. Panková K., Rosel D., Novotný M., Brábek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell. Mol. Life Sci. 2010, 67:63-71.
19. Pinner S., Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat. Cell Biol. 2008, 10:127-137.
20. Rosel D., Brábek J., Tolde O., Mierke C.T., Zitterbart D.P., Raupach C., Bicanová K., Kollmannsberger P., Panková D., Vesely P., Folk P., Fabry B. Up-regulation of Rho/ROCK signaling in sarcoma cells drives invasion and increased generation of protrusive forces. Mol. Cancer Res. 2008, 6:1410-1420.
21. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003, 5:711-719.
22. Sanz-Moreno V., Gadea G., Ahn J., Paterson H., Marra P., Pinner S., Sahai E., Marshall C.J. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
23. Schnell L., Schwab M.E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990, 343:269-272.
24. Smith F.O., Rauch C., Williams D.E., March C.J., Arthur D., Hilden J., Lampkin B.C., Buckley J.D., Buckley C.V., Woods W.G., Dinndorf P.A., Sorensen P., Kersey J., Hammond D., Bernstein I.D. The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996, 873:1123-1133.
25. Stallcup W.B., Dahlin K., Healy P. Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J. Cell Biol. 1990, 111:3177-3188.
26. Stallcup W.B., Huang F.J. A role for the NG2 proteoglycan in glioma progression. Cell Adh. Migr. 2008, 2:192-201.
27. Tillet E., Ruggiero F., Nishiyama A., Stallcup W.B. The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J. Biol. Chem. 1997, 272:769-776.
28. Tillet E., Gential B., Garrone R., Stallcup W.B. NG2 proteoglycan mediates beta1 integrin-independent cell adhesion and spreading on collagen VI. J. Cell. Biochem. 2002, 86:726-736.
29. Tolde O., Rosel D., Veselý P., Folk P., Brábek J. The structure of invadopodia in a complex 3D environment. Eur. J. Cell Biol. 2010, 89:674-680.
30. Wang X., Wang Y., Yu L., Sakakura K., Visus C., Schwab J.H., Ferrone C.R., Favoino E., Koya Y., Campoli M.R., McCarthy J.B., DeLeo A.B., Ferrone S. CSPG4 in cancer: multiple roles. Curr. Mol. Med. 2010, 10:419-429.
31. Wolf K., Mazo I., Leung H., Engelke K., von Andrian U.H., Deryugina E.I., Strongin A.Y., Bröcker E.B., Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
32. Wyckoff J.B., Pinner S.E., Gschmeissner S., Condeelis J.S., Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr. Biol. 2006, 16:1515-1523.